Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peng-Fei Zhang

Showing results (11-20 of 271) with videos related to

Pageof 28
Sort By:
Immunotherapy|July 31, 2020
Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospectsPeng-Fei Zhang, Dan Xie, Qiu Li
Frontiers in Public Health|February 26, 2021
Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness AnalysisPeng-Fei Zhang, Dan Xie, Qiu Li
BMC Cancer|January 8, 2021
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistancePeng-Fei Zhang, Dan Xie, Qiu Li
Cost Effectiveness and Resource Allocation : C/E|September 13, 2023
Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysisPeng-Fei Zhang, Xuan-Qiong Shi, Qiu Li
Immunotherapy|March 2, 2022
Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cellsPeng-Fei Zhang, Chuang Wang, Le Zhang, et al.
Environmental Technology|February 27, 2013
Hydrothermal treatment of incineration fly ash for PCDD/Fs decomposition: the effect of iron additionDe-Zhen Chen, Yu-Yan Hu, Peng-Fei Zhang
Cancer Medicine|June 4, 2020
Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysisPeng-Fei Zhang, Dan Xie, Feng Wen, et al.
Journal of Comparative Effectiveness Research|August 4, 2022
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysisPeng-Fei Zhang, Feng Wen, Qiu-Ji Wu, et al.
Molecular Neurobiology|March 13, 2021
Microglia Biomarkers in Alzheimer's DiseasePeng-Fei Zhang, Hao Hu, Lan Tan, et al.
Toxicon : Official Journal of the International Society on Toxinology|August 2, 2003
Huwentoxin-V, a novel insecticidal peptide toxin from the spider Selenocosmia huwena, and a natural mutant of the toxin: indicates the key amino acid residues related to the biological activityPeng-Fei Zhang, Ping Chen, Wei-Jun Hu, et al.
Pageof 28

Showing results (11-20 of 271) with videos related to

Sort By:
Pageof 28
Immunotherapy|July 31, 2020
Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospectsPeng-Fei Zhang, Dan Xie, Qiu Li
Frontiers in Public Health|February 26, 2021
Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness AnalysisPeng-Fei Zhang, Dan Xie, Qiu Li
BMC Cancer|January 8, 2021
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistancePeng-Fei Zhang, Dan Xie, Qiu Li
Cost Effectiveness and Resource Allocation : C/E|September 13, 2023
Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysisPeng-Fei Zhang, Xuan-Qiong Shi, Qiu Li
Immunotherapy|March 2, 2022
Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cellsPeng-Fei Zhang, Chuang Wang, Le Zhang, et al.
Environmental Technology|February 27, 2013
Hydrothermal treatment of incineration fly ash for PCDD/Fs decomposition: the effect of iron additionDe-Zhen Chen, Yu-Yan Hu, Peng-Fei Zhang
Cancer Medicine|June 4, 2020
Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysisPeng-Fei Zhang, Dan Xie, Feng Wen, et al.
Journal of Comparative Effectiveness Research|August 4, 2022
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysisPeng-Fei Zhang, Feng Wen, Qiu-Ji Wu, et al.
Molecular Neurobiology|March 13, 2021
Microglia Biomarkers in Alzheimer's DiseasePeng-Fei Zhang, Hao Hu, Lan Tan, et al.
Toxicon : Official Journal of the International Society on Toxinology|August 2, 2003
Huwentoxin-V, a novel insecticidal peptide toxin from the spider Selenocosmia huwena, and a natural mutant of the toxin: indicates the key amino acid residues related to the biological activityPeng-Fei Zhang, Ping Chen, Wei-Jun Hu, et al.
Pageof 28